跳至主要内容
临床试验/EUCTR2015-003453-18-DK
EUCTR2015-003453-18-DK进行中(未招募)1 期

A Randomized, Single-blinded, Cross-over Study investigating the Non-inferiority of Efficacy and Safety of HyQvia in comparison with Conventional Subcutaneous Ig Therapy in Multifocal Motor Neuropathy

Rigshospitalet0 个研究点目标入组 20 人开始时间: 2015年9月23日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Presence of asymmetrical limb weakness at onset or motor involvement having a motor nerve distribution in at least two peripheral nerve distributions, predominant upper limb involvement, disabling weakness MRC grade 4 or less in at least one muscle group.
  • Decreased or absent tendon reflexes in affected limbs.
  • Electrophysiological evidence of one site with definite motor conduction block or one site with propable conduction block according to previously defined criteria.
  • Response to subcutaneous immunoglobulin according to criteria described in previous studies.
  • On subcutaneous immunoglobulin maintenance treatment prior to enrolment.
  • Age at onset 18-65 years.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 15
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 5

排除标准

  • Bulbar signs or symptoms.
  • Upper motor neuron signs (spasticity, hyperreflexia, extensor plantar response).
  • Sensory symptoms and signs with sensory deficits on examination (except for vibration sense) and abnormal results of sensory nerve conduction studies.
  • Other neuropathies (e.g. diabetic, lead, porphyric or vasculitic neuropathy, chronic inflammatory demyelinating polyneuropathy, Lyme neuroborreliosis, post radiation neuropathy, hereditary neuropathy with liability to pressure palsies, Charcot-Marie-Tooth neuropathies, meningeal carcinomatosis).
  • Treatment with other immunosuppressive drugs (cyclophosphamide, azathioprine, cyclosporin) in the 6 months preceding the study.
  • Female patient who is pregnant or breast-feeding or of childbearing potential.
  • Confirmation that the patient is not pregnant will be established by a negative b-HCG test within a 7-day period before inclusion in the study. Lack of childbearing potential is met by a) being post-menopausal, b) being surgically sterile, c) practicing contraception with an oral contraceptive, intra-uterine device, diaphragm or condom with spermacide or d) being sexually inactive.

研究者

相似试验